403.000USD+403.000盘后交易 06/24, 20:00 (美东)
关键数据
403.560今开
407.330最高
2.71M成交量
48.21市盈率 TTM
33.80市盈率动
--股息TTM
0.76%换手率
402.950昨收
399.370最低
871.58M成交额
61.52市盈率静
8.18市净率
0.00%股息率 TTM
15.25%ROA
603.88052周最高
0.98量比
2.32B净利润
354.40M总股本
8.3634每股收益TTM
1.65Beta
17.23%ROE
425.00052周最低
1.98%振幅
66.06%毛利率
142.79B总市值
-4.91回报/风险
1.63%风险率
操作建议
直觉外科当前公司基本面数据相对非常健康,增长潜力很大。当前估值合理,在医疗设备与耗材行业排名40/204位。机构持股占比非常高,近一月多位分析师给出公司评级为买入。最高目标价570.92。中期看,股价处于下降通道。近一个月,市场表现较差,但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间,可以做区间波段操作。
压力支撑

由于公司未披露,未能获取相关数据
数据免责声明:分析师评级与目标价由LSEG提供,仅供参考,不应当作投资建议
财务指标
每股收益

由于公司未披露,未能获取相关数据
营业总收入

由于公司未披露,未能获取相关数据
直觉外科简介
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
公司代码ISRG
公司直觉外科
CEORosa (David J)
网址https://www.intuitive.com/en-us/about-us/company
常见问题
现在直觉外科(ISRG)的股票是买入、持有还是卖出?
根据分析师评级,直觉外科(ISRG)的总体评级为买入,目标价格为570.92。
直觉外科(ISRG)股票的每股收益(EPS TTM)是多少
直觉外科(ISRG)股票的每股收益(EPS TTM)是8.00。